06 jun: Forhåndstilkendegivelse på ordre
06 jun: Indre værdi af SmallCap Danmark A/S er opgjort til 10,7 kr. pr. a..
06-06-2019 08:00:00

Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion

  • First home-use trial of the iLet Bionic Pancreas System using pre-filled cartridges of dasiglucagon compatible with iLet has been successfully completed

     

  • The preliminary study results reveal superior blood glucose control during the study period that used the bihormonal configuration of the iLet with dasiglucagon compared to the period that used the insulin-only configuration

     

  • iLet therapy was initialized with body weight only, with no device training periods, and with no physician intervention to optimize therapy

 

Boston, MA and Copenhagen, Denmark – June 6, 2019 – Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL, company announcement No. 19/2019) announced today that a home-use study of dasiglucagon in the iLet™ Bionic Pancreas System has been successfully completed.   

The iLet, developed by Beta Bionics, is the world’s first autonomous bionic pancreas device — a bihormonal system leveraging lifelong machine learning and artificial intelligence to deliver insulin and glucagon analogs for the autonomous treatment of type 1 diabetes (T1D). In addition to dosing insulin, the iLet doses dasiglucagon — a glucagon analog with a unique stability profile in a ready-to-use aqueous solution.  Dasiglucagon is in development by Zealand Pharma.

This home-use clinical trial was conducted by Dr. Steven Russell and his clinical research team at the Massachusetts General Hospital (MGH) and was designed as a randomized, two-period, cross-over trial to assess whether the iLet operated as intended.  The trial compared operational performance of the iLet in the insulin-only configuration for one week versus the bihormonal configuration for one week in 10 adult participants with T1D.  Trial participants started therapy by entering only their body weight into the device; there was no device training period and no physician intervention to optimize therapy. The iLet is designed to autonomously and continuously adapt to each patient’s changing insulin needs.  This adaptation is typically most pronounced in the first 24 hours after the initiation of therapy.

The iLet operated as expected, meeting the primary aim of the study.  Preliminary data analysis demonstrated that the bihormonal iLet using dasiglucagon provided superior glycemic control over the insulin-only iLet.  During the bihormonal period, participants achieved a mean glucose level, as measured by continuous glucose monitoring (CGM), of 139 mg/dL on days 2–7 of use, versus 149 mg/dL during the insulin-only period (p <0.01).  during="" the="" bihormonal="" period,="" participants="" spent="" 79%="" of="" the="" time="" with="" their="" cgm="" glucose="" level="" in="" range="" (70–180="" mg/dl)="" on="" days="" 2–7="" of="" use,="" versus="" 71%="" during="" the="" insulin-only="" period="">p<0.01). during="" the="" bihormonal="" period,="" 90%="" of="" participants="" had="" a="" mean="" cgm="" glucose="" level="" of="">< 154="" mg/dl,="" a="" level="" that="" corresponds="" to="" an="" hba1c="" level="" of="" 7%,="" the="" therapeutic="" goal="" for="" adults="" recommended="" by="" the="" american="" diabetes="" association.="" in="" contrast,="" 50%="" of="" participants="" had="" a="" mean="" cgm="" glucose="" level="">< 154="" mg/dl="" during="" the="" insulin-only="">

Hypoglycemia was observed to be low throughout the study.  The mean percentage of time CGM glucose was < 54="" mg/dl="" was="" 0.3%="" during="" the="" bihormonal="" period="" versus="" 0.6%="" during="" the="" insulin-only="" period. ="" the="" mean="" percentage="" of="" time="" cgm="" glucose="" was="">< 70="" mg/dl="" was="" 2.4%="" during="" the="" bihormonal="" period="" versus="" 3.6%="" during="" the="" insulin-only="">

“We are extremely pleased to have now tested the performance of our bihormonal iLet Bionic Pancreas System with dasiglucagaon — the first-ever, liquid-stable glucagon analog — in a convenient ready-to-use, pre-filled cartridge designed to fit our system,” said Ed Damiano, Co-founder and President & CEO of Beta Bionics. “Preliminary results from this trial have helped reaffirm the final implementation of our dosing algorithms in the bihormonal configuration of the iLet.  I am ecstatic about this historic achievement for Beta Bionics, Zealand Pharma, and our clinical collaborators at MGH, and I am looking forward with eager anticipation to the day when people with T1D can enjoy the real-life benefits of combining ready-to-use dasiglucagon with the iLet.”

Beta Bionics and Zealand Pharma have partnered to carry out several co-development activities with the primary goal of obtaining regulatory approval to use dasiglucagon in the bihormonal configuration of the iLet.  

“The bihormonal iLet Bionic Pancreas System demonstrated tight glycemic control in a home-use setting with dasiglucagon,” commented Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “We look forward to proceeding with the Phase 3 trial and continuing to demonstrate the transformational opportunity that the iLet with dasiglucagon could offer for improved and fully automated diabetes management.”

Beta Bionics and Zealand Pharma are planning for a Phase 3 pivotal trial testing the bihormonal configuration of the iLet with dasiglucagon in 2020.  That trial is intended to support regulatory submission to the U.S. FDA of a pre-market approval (PMA) application and a new drug application (NDA) for the bihormonal configuration of the iLet with dasiglucagon in people with T1D. 

 

About the iLet

The iLet bionic pancreas system is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes. The dosing control algorithms integrated into the iLet were licensed by Beta Bionics from Boston University.  In previous home-use studies in adults and children with T1D, these algorithms demonstrated dramatic improvements in glycemic control relative to the standard of care.  These improvements included significant reductions in blood-glucose levels, in hypoglycemia, and in intersubject and intrasubject glycemic variability (New England Journal of Medicine. 2014, 371:313-25; Lancet Diabetes and Endocrinology. 2016, 4:233-43; Lancet. 2016, 389:369-80). 

To initialize the iLet, users enter only their body weight.  Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.  The iLet is effectively three medical devices in one.  It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas (insulin and glucagon).  The glucagon-only configuration may be helpful in rare, chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI) and insulinoma syndrome.  Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.

About dasiglucagon for use in other indications

Dasiglucagon is a Zealand Pharma-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of severe hypoglycemia, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).

 

About Beta Bionics

Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas system that is driven by mathematical dosing algorithms to autonomously control glycemia.  These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D.  Beta Bionics is a Certified B Corporation™ whose founders—in addition to Ed Damiano—include other parents of children with type 1 diabetes and people with type 1 diabetes.  Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible. 

Beta Bionics is operated out of Boston, Massachusetts and Irvine, California. For further information, please visit www.betabionics.com or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter @BetaBionics.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. 

 

Company Contacts

Beta Bionics

Zealand Pharma

 

Ed Damiano

edamiano@betabionics.com

 

Ed Raskin

eraskin@betabionics.com

 

Investor Relations Contact

Jeremy Feffer

jeremy@lifesciadvisors.com

 

 

Emmanuel Dulac

President and Chief Executive Officer

DK: +45 50 60 36 36

US: +1 857 777 6060

edu@zealandpharma.com

 

Lani Pollworth Morvan

Investor Relations and Communication

Tel.: +45 50 60 37 78

lpm@zealandpharma.com

 

 

Attachment

Beta Bionics logo

Zealand Pharma logo

Relateret indhold
03 jun - 
Zealand Pharma/Bryan Garnier: Løfter kursmål til 180 kr..
24 maj - 
Zealand Pharma/SHB: Kursmålet løftes mens anbefalingen ..
22 maj - 
Onsdagens aktier: Overbevisende regnskab sendte Simcorp..
Relateret debat
16 jul - 
Jeg solgt lidt i luk i dag men det var ikke så meget.
16 jul - 
Zealand Pharma er i øvrigt oppen med 83,25% iår!
16 jul - 
Pænt luk i kurs 151 Endog med stor vulumen 26,4K i lukk..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 jul
ZEAL
Pænt luk i kurs 151   Endog med stor vulumen 26,4K i lukkeauktionen :-)Hvem tør være ude ....   www...
3
12 jul
ZEAL
Ja, så vafventer vi næste trin i 160
3
12 jul
ZEAL
Griner kommer ikke i 100 mere og Velo kommer ikke i 1 kr igen.. så meget godt du ikke var med😅
2
12 jul
ZEAL
Og ja, først skal den tidligere top i kurs 169 brydes ...
1
12 jul
ZEAL
Investtech d.d.: "Videre stigning til 190 eller mere er signaleret."   Men derfor kan ZP sagtens fal..
1
12 jul
ZEAL
Om ikke andet så er CFO-annonceringen og nødpen-partneraftalen tætter på!
1
12 jul
ZEAL
Dejlig stigning, men man skal aldrig sige aldrig,  sidst den var heroppe, troede man kurs 80 var umu..
1
12 jul
ZEAL
Jeg ærgrer mig over at jeg ikke har været med på stigningen. Havde ikke drømt om at kursen kunne sti..
1
12 jul
ZEAL
Det er godt at se at 150 er brudt klart!
1
12 jul
ZEAL
Kurs 151, steget 4,7 point i dag.   Er der nyt, vi små ikke ved endnu?
1

Goldman Sachs: Højere indtægter kravlede ikke med på bunden

16-07-2019 13:51:32
Indtægterne fra aktiehandel, som er et vigtigt område for den amerikanske storbank Goldman Sachs, klarede sig bedre end analytikerne havde ventet i andet kvartal. Men selv om de samlede indtægter også steg en smule, bevægede de sig ikke med ned på bundlinjen i regnskabet for kvartalet.Det skriver Bloomberg News.På bundlinjen præsenterede den New York-baserede bank et overskud på 5,81 dollar per ak..

Aktier/tendens: Stilstand på sommertynde markeder - Genmab i fokus

16-07-2019 08:06:06
Genmab kan komme i fokus tirsdag, når det amerikanske medicinalselskab Johnson & Johnson over middag kommer med regnskab for andet kvartal af 2019, da det fortæller, hvordan det globale salg af kræftmidlet Darzalex arter sig.Samlet peger det på en forholdsvis neutral åbning på det danske aktiemarked, hvis retningen skal tages efter futures for det tyske DAX-indeks, der ligger til et svagt plus.Man..

Kina fremviser sløjeste vækst i årtier midt i handelskrig

Relaterede nyheder
15-07-2019 13:28:01
Kineserne må vænne sig til, at økonomien ikke længere buldrer afsted.Tocifrede vækstrater er fortid, og det bliver mandag understreget af nye tal for landets økonomi.I andet kvartal voksede Kinas bruttonationalprodukt med 6,2 procent. Det er den sløjeste fremgang i omkring tre årtier, skriver nyhedsbureauet Reuters.De økonomiske data fra Kina er under stor bevågenhed på grund af den handelskonflik..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Trumps importafgifter tjener ikke nok til at dække omkostninger
2
Genmab: Johnson & Johnson salg af Darzalex overrasker
3
Vestas lander ordre på 415 MW i Saudi Arabien - NY
4
Vestas: Tabel med ordrer annonceret i 2019
5
Genmab/Sydbank: Dazalex-salget uden for USA overrasker

Relaterede aktiekurser

Zealand Pharma A/S 151,00 2,0% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 151,00 2,0% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. juli 2019 08:38:51
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB3 - 2019-07-17 08:38:51 - 2019-07-17 08:38:51 - 1 - Website: OKAY